Ignite Creation Date:
2024-05-11 @ 8:30 AM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06406634
Status:
RECRUITING
Last Update Posted:
2024-05-09
First Post:
2024-04-07
Brief Title:
Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy HAIC for the Treatment of Unresectable Hepatocellular Carcinoma
Sponsor:
Hunan Cancer Hospital
Organization:
Hunan Cancer Hospital
Study Overview
Official Title:
Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy HAIC for the Treatment of Unresectable Hepatocellular Carcinoma
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is an open-label multicenter single-arm Phase II clinical study to evaluate the effectiveness of CadonilimabAK104 in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy HAIC for the Treatment of Unresectable Hepatocellular Carcinoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None